NexImmune, Inc.
NexImmune, Inc. (NEXI): 5 pipeline candidates · ~4 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
3.8 months
D/E 7.10 · 0% dilution
Lead: Phase 2
5 candidates
N/A
N/A
A transparent, data-derived signal for NexImmune, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$139
Cash
$2.4M
Quarterly Burn
$2.1M
Runway
3.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
Frequently asked questions
How many drug candidates are in NexImmune, Inc.'s pipeline?
NexImmune, Inc. (NEXI) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is NexImmune, Inc.'s lead drug candidate?
NexImmune, Inc.'s most advanced tracked candidate is nexi-001 (Phase 2) for Acute myeloid leukemia (AML) in patients who have relapsed post allo-stem cell transplant.
What is NexImmune, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, NexImmune, Inc. has approximately 3.8 months of cash runway.
What is NexImmune, Inc.'s market capitalization?
NexImmune, Inc.'s market capitalization is approximately $139.
Who is the CEO of NexImmune, Inc.?
Series A Preferred Stock is the chief executive officer of NexImmune, Inc. (NEXI).
Get the full picture on NexImmune, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.